Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 21, 2021updated 25 Jun 2021 1:01pm

LoA Update: Centrexion Therapeutics’ CNTX-4975 approval likelihood in osteoarthritis-related knee pain increases by five points after Phase III trial completion

Centrexion Therapeutics’ CNTX-4975 Likelihood of Approval (LoA) in osteoarthritis-associated knee pain went up by 5 points to 30% after a Phase III trial was completed, as of 16 June.

Centrexion Therapeutics’ CNTX-4975 Likelihood of Approval (LoA) in osteoarthritis-associated knee pain went up by 5 points to 30% after a Phase III trial was completed, as of 16 June.

The Phase III study is evaluating CNTX-4975, a formulation of transcapsaicin that targets TRPV1. The drug is injected directly into the joint and intended to disrupt pain-sensing nerve fibre signalling locally and selectively. CNTX-4975 is being tested as a treatment for chronic moderate-to-severe osteoarthritis knee pain and the study is one of three Phase III trials evaluating CNTX-4975 in that indication. The trial’s entry on ClinicalTrials.gov was changed to “completed” on 14 June, but results have not been added.

Boston, Massachusetts-based Centrexion had raised $40.5m in October 2020 to develop and in-license drug candidates. CNTX-4975 is one of its lead candidates and it was granted a Fast Track designation for the treatment of moderate-to-severe pain associated with knee osteoarthritis in 2018.

With this change, the drug’s Phase Transition Success Rate (PTSR) also went up by 7 points to 44%. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The LoA metric is calculated by compounding the PTSR at each stage the drug is yet to progress through and uses and uses a combination of machine learning and a proprietary algorithm.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU